Trials Sponsors Conditions Drugs Pricing

Conditions

Tumor Burden Neuroendocrine (NE) Tumors

Keywords

Tumor BurdenNeuroendocrine Tumors

Outcome Measures

Primary Outcomes (1)

Progression-Free Survival (PFS)
Progression-free survival, defined as the time from treatment initiation to documented disease progression. Patients without documented progression at the end of follow-up will be censored at the date of the last follow-up without progression.
From treatment initiation until the first documented disease progression or death from any cause, whichever occurs first, assessed up to 120 months.

Secondary Outcomes (2)

Objective Response Rate (ORR)
From treatment initiation until disease progression or the last tumor response assessment, assessed up to 120 months.
Overall Survival (OS)
From treatment initiation until death from any cause or last follow-up, assessed up to 120 months.

Other Outcomes (6)

Incidence of Grade 3-4 Adverse Events According to CTCAE
From treatment initiation until treatment discontinuation or the last available safety assessment, assessed up to 120 months.
Correlation of Chromogranin A, 5-HIAA, and Neuron-Specific Enolase Levels With TB-NET Score
At baseline, prior to treatment initiation.
Percentage of Patients With Positive Baseline 18F-FDG PET/CT According to TB-NET Score Risk Group
At baseline, prior to treatment initiation.
+3 more other outcomes

Study Arms (1)

Patients With Advanced Well-Differentiated NETs

Adult patients with histologically confirmed well differentiated advanced GEP-NETs or Lung Carcinoids starting any line of systemic therapy.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Patients with histologically confirmed well differentiated advanced GEP-NETs or Lung Carcinoids starting any line of systemic therapy.

You may qualify if:

Adult patients with histologically confirmed well differentiated advanced GEP-NETs or Lung Carcinoids starting any line of systemic therapy.

Sponsors & Collaborators

University of Lausanne Hospitals
Othercollaborator
Dana-Farber Cancer Institute
Othercollaborator
Skane University Hospital

Study Sites (11)

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States

RECRUITING

Jennifer Chan, MDCONTACT617-632-3000 jennifer_chan@dfci.harvard.edu

Mallinckrodt Institute of Radiology

St Louis, Missouri, 63110, United States

RECRUITING

Prasad Vikas, MDCONTACT314-362-1474

MeSH Terms

Conditions

NeoplasmsNeuroendocrine Tumors

Condition Hierarchy (Ancestors)

Neuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasms, Nerve Tissue

Study Officials

Angela Lamarca, MD, PhD
Hospital Universitario Fundación Jiménez Díaz
PRINCIPAL INVESTIGATOR

Central Study Contacts

Angela Lamarca, MD, PhD

CONTACT

+34 915504800 angela.lamarca@quironsalud.es

Diego Fernández, MD

CONTACT

+34 636284882

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

September 30, 2026

First Posted

October 29, 2026

Study Start

May 12, 2026

Actual (reported)

Primary Completion

March 2027

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Multicenter Study for External Validation of the TB-NET Score

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Other Outcomes (6)

Study Arms (1)

Patients With Advanced Well-Differentiated NETs

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (11)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Other Outcomes (6)

Study Arms (1)

Patients With Advanced Well-Differentiated NETs

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (11)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations